Skip to main content
Ganga Pharmaceuticals Limited logo

Ganga Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 539680 ISIN · INE615T01017 BSE.NS Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS 539680

About Ganga Pharmaceuticals Limited

https://www.ayurvedganga.com

Ganga Pharmaceuticals Limited specializes in the development, manufacturing, and marketing of Ayurvedic medicines and pharmaceutical formulations. The company integrates traditional herbal knowledge with modern manufacturing techniques to produce a diverse range of healthcare solutions. Its product portfolio encompasses various dosage forms, including tablets, capsules, syrups, and ointments, catering to multiple therapeutic areas. A significant portion of its operations is dedicated to proprietary Ayurvedic products designed for holistic health management. The organization maintains a focus on quality assurance and standardized production processes to ensure the consistency and safety of its medicinal offerings.

Recent filings

Filing Released Lang Actions
Appointment of Secretarial Auditor
Regulatory Filings Classification · 80% confidence The document is an SEBI Listing Regulations (Regulation 30) intimation to the stock exchange disclosing the appointment of a Secretarial Auditor. It is a regulatory announcement rather than a full financial report, management discussion, or board meeting minutes regarding directors. There is no in-depth financial data or formal report attached. This falls under general regulatory filings and miscellaneous exchange disclosures (fallback category). Therefore, the appropriate classification is Regulatory Filings (Code: RNS).
2026-05-21 English
Appointment of Internal Auditor
Regulatory Filings Classification · 80% confidence The document is an SEBI Listing Regulations, Regulation 30 disclosure announcing the Board’s approval for the appointment of an internal auditor. It is a regulatory announcement under listing compliance and does not present financial statements or constitute a full report itself. It does not fit audit report content (AR), management/board changes (MANG is for board/senior management roles), or any other specific category. Therefore, it is a general regulatory filing announcement under RNS.
2026-05-21 English
Audited Financial Results of the Company for the half yeaar and financial year ended March 31, 2026
Interim / Quarterly Report Classification · 90% confidence The document is a formal SEBI Listing Regulations filing (Regulations 30 & 33) announcing the Board’s approval of the audited financial results for the half‐year and financial year ended March 31, 2026. It includes the full audited half‐year and year‐to‐date financial statements and the independent auditor’s report—i.e., substantive interim financial data, not just a high‐level earnings release or an attached 10-K or full annual report. This matches the definition of an Interim/Quarterly Report (IR) because it covers a period less than a full fiscal year (the half year) and provides comprehensive financial statements. FY 2026
2026-05-21 English
Outcome of the Board Meeting held on May 21, 2026
Interim / Quarterly Report Classification · 87% confidence The document is an SEBI Listing Regulations filing containing the Statutory Auditor’s Report and the actual audited standalone financial results (P&L, EPS, notes) for the half‐year (six months) and full financial year ended March 31, 2026. It is not a short notice that a report is “attached” (so not an RPA), nor is it a full annual report with all disclosures. It contains substantive financial statements for a period shorter than a full fiscal year (half‐year) and thus fits the definition of an Interim/Quarterly Report. FY 2026
2026-05-21 English
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Regulatory Filings Classification · 85% confidence The document is a formal intimation to the stock exchange under SEBI (Listing Obligations and Disclosure Requirements) Regulation 29 notifying the date of a Board Meeting to consider and approve audited financial results. It does not present any financial statements itself nor announce changes in directors/management, so it is not an Interim/Quarterly Report (IR), Annual Report (10-K), or Board/Management change notice (MANG). Rather, it is a routine regulatory announcement (“notice of board meeting”) making it a general Regulatory Filing (RNS).
2026-05-14 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.